Cargando…

外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义

OBJECTIVE: To evaluate the prognostic value of lymphocyte to monocyte ratio (LMR) and PET scan performed after first two cycles of chemotherapy (PET-2) in Hodgkin's lymphoma (HL). METHODS: The clinical data of 133 patients with HL diagnosed from January 2007 to March 2016 at the First Affiliate...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342242/
https://www.ncbi.nlm.nih.gov/pubmed/31207700
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.05.005
_version_ 1783555416510169088
collection PubMed
description OBJECTIVE: To evaluate the prognostic value of lymphocyte to monocyte ratio (LMR) and PET scan performed after first two cycles of chemotherapy (PET-2) in Hodgkin's lymphoma (HL). METHODS: The clinical data of 133 patients with HL diagnosed from January 2007 to March 2016 at the First Affiliated Hospital of Nanjing Medical University, were retrospectively analyzed. The X-tile software was used to calculate the optimal cut-off value of LMR. Kaplan-Meier method and Cox regression were used for survival analysis. RESULTS: The median age of 133 HL patients was 33 (18–84) years, and the male to female ratio was 1.9∶1. The optimal cut-off value of LMR was 2.5, and progression free survival (PFS) (P<0.001) and overall survival (OS) (P<0.001) were significantly lower in the LMR<2.5 group than that of LMR≥2.5. Multivariate survival analysis showed that LMR<2.5 was an independent predictor of PFS (P=0.002, HR=2.35, 95%CI 1.36–4.07) and OS (P=0.002, HR=10.36, 95%CI 2.35–45.66) in HL patients. The analysis of PET-2 from 56 HL patients showed that PET-2 positive patients had significantly poorer PFS (P=0.022). After grouping LMR combined with PET-2, significant differences were found in PFS and OS between the three groups (P values were 0.009 and 0.012). CONCLUSION: LMR<2.5 is an independent prognostic factor for patients with HL. PET-2 combined with LMR may have better prognostic value.
format Online
Article
Text
id pubmed-7342242
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73422422020-07-16 外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To evaluate the prognostic value of lymphocyte to monocyte ratio (LMR) and PET scan performed after first two cycles of chemotherapy (PET-2) in Hodgkin's lymphoma (HL). METHODS: The clinical data of 133 patients with HL diagnosed from January 2007 to March 2016 at the First Affiliated Hospital of Nanjing Medical University, were retrospectively analyzed. The X-tile software was used to calculate the optimal cut-off value of LMR. Kaplan-Meier method and Cox regression were used for survival analysis. RESULTS: The median age of 133 HL patients was 33 (18–84) years, and the male to female ratio was 1.9∶1. The optimal cut-off value of LMR was 2.5, and progression free survival (PFS) (P<0.001) and overall survival (OS) (P<0.001) were significantly lower in the LMR<2.5 group than that of LMR≥2.5. Multivariate survival analysis showed that LMR<2.5 was an independent predictor of PFS (P=0.002, HR=2.35, 95%CI 1.36–4.07) and OS (P=0.002, HR=10.36, 95%CI 2.35–45.66) in HL patients. The analysis of PET-2 from 56 HL patients showed that PET-2 positive patients had significantly poorer PFS (P=0.022). After grouping LMR combined with PET-2, significant differences were found in PFS and OS between the three groups (P values were 0.009 and 0.012). CONCLUSION: LMR<2.5 is an independent prognostic factor for patients with HL. PET-2 combined with LMR may have better prognostic value. Editorial office of Chinese Journal of Hematology 2019-05 /pmc/articles/PMC7342242/ /pubmed/31207700 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.05.005 Text en 2019年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义
title 外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义
title_full 外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义
title_fullStr 外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义
title_full_unstemmed 外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义
title_short 外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义
title_sort 外周血淋巴细胞/单核细胞比值及2个疗程后pet评价在成人霍奇金淋巴瘤中的预后意义
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342242/
https://www.ncbi.nlm.nih.gov/pubmed/31207700
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.05.005
work_keys_str_mv AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì
AT wàizhōuxuèlínbāxìbāodānhéxìbāobǐzhíjí2gèliáochénghòupetpíngjiàzàichéngrénhuòqíjīnlínbāliúzhōngdeyùhòuyìyì